Zevra Therapeutics, Inc. (ZVRA) Stock Forecast
Data as of Aug 1, 2026Healthcare · Current price $9.61 (-0.36%)
Price Target Range
Consensus Price Target Over Time
Analyst Rating Distribution
Last 3 Months
6-Month Trend
Latest Analyst Forecasts
Price targets issued by Wall Street analysts. Upside calculated against today's price.
| Date | Analyst | Firm | Price Target | Upside |
|---|---|---|---|---|
| Mar 10, 2026 | Eddie Hickman | Guggenheim | $23.00 | +139.3% |
| Dec 30, 2025 | Brandon Folkes | H.C. Wainwright | $26.00 | +170.6% |
| Nov 6, 2025 | Kristen Kluska | Cantor Fitzgerald | $24.00 | +149.7% |
| Feb 4, 2025 | Zevra Therapeutics to $ | Guggenheim | $21.00 | +118.5% |
| Sep 24, 2024 | Jonathan Aschoff | Roth Capital | $21.00 | +118.5% |
| Sep 24, 2024 | Jason McCarthy | Maxim Group | $25.00 | +160.1% |
| Sep 24, 2024 | Jason Butler | JMP Securities | $17.00 | +76.9% |
| Sep 23, 2024 | Oren Livnat | H.C. Wainwright | $20.00 | +108.1% |
| Sep 18, 2024 | Sumant Kulkarni | Canaccord Genuity | $22.00 | +128.9% |
Top Analysts Covering ZVRA
ZVRA vs Sector & Market
| Metric | ZVRA | Healthcare Avg | Large Cap Avg |
|---|---|---|---|
| Analyst Rating | 2.00 | 2.25 | 2.42 |
| Analyst Count | 12 | 8 | 19 |
| Target Upside | +221.6% | +16365.9% | +18.0% |
| P/E Ratio | 4.47 | 3.01 | 43.33 |
Revenue Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $137M | $143M | $154M | 7 |
| 2027-03-31 | $45M | $48M | $53M | 3 |
| 2027-06-30 | $49M | $52M | $58M | 3 |
| 2027-09-30 | $52M | $56M | $62M | 3 |
| 2027-12-31 | $55M | $59M | $66M | 3 |
| 2028-03-31 | $60M | $64M | $71M | 2 |
| 2028-06-30 | $63M | $67M | $75M | 2 |
| 2028-09-30 | $68M | $73M | $81M | 2 |
| 2028-12-31 | $71M | $75M | $84M | 2 |
| 2029-12-31 | $327M | $361M | $443M | 3 |
| 2030-12-31 | $368M | $407M | $498M | 6 |
EPS Estimates
| Period | Low | Avg | High | # |
|---|---|---|---|---|
| 2026-12-31 | $0.25 | $0.49 | $0.82 | 7 |
| 2027-03-31 | $0.27 | $0.30 | $0.34 | 1 |
| 2027-06-30 | $0.32 | $0.35 | $0.40 | 1 |
| 2027-09-30 | $0.35 | $0.38 | $0.44 | 1 |
| 2027-12-31 | $0.38 | $0.41 | $0.48 | 1 |
| 2028-03-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-06-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-09-30 | $0.00 | $0.00 | $0.00 | 2 |
| 2028-12-31 | $0.00 | $0.00 | $0.00 | 2 |
| 2029-12-31 | $2.67 | $3.04 | $3.94 | 2 |
| 2030-12-31 | $3.00 | $3.42 | $4.42 | 5 |
Frequently Asked Questions
What is the analyst consensus for ZVRA?
The consensus among 12 analysts covering Zevra Therapeutics, Inc. (ZVRA) is Buy with an average price target of $25.50.
What is the highest price target for ZVRA?
The highest price target for ZVRA is $26.00, set by Brandon Folkes at H.C. Wainwright on 2025-12-30.
What is the lowest price target for ZVRA?
The lowest price target for ZVRA is $17.00, set by Jason Butler at JMP Securities on 2024-09-24.
How many analysts cover ZVRA?
12 analysts have issued ratings for Zevra Therapeutics, Inc. in the past 12 months.
Is ZVRA a buy or sell right now?
Based on 12 analyst ratings, ZVRA has a consensus rating of Buy (2.00/5) with a +221.6% upside to the consensus target of $25.50.
What are the earnings estimates for ZVRA?
Analysts estimate ZVRA will report EPS of $0.49 for the period ending 2026-12-31, with revenue estimated at $143M.
Related Stock Forecasts
Data updated daily. Analyst price targets sourced from public filings and broker reports. Not investment advice.